J&J launches tender offer for Crucell
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has launched its tender offer for Crucell, easing fears that it might back-out of the acquisition over manufacturing concerns at the Dutch biotech's manufacturing facility in South Korea.